Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Geminus Therapeutics
AddedMar 20, 2024
UpdatedJun 18, 2026
Geminus Therapeutics

Geminus Therapeutics

Leading leukemia cure developer with ART714 treatment.

HQ
Baltimore, MD, US
Overview
Compare
Fundraising
Employees

Geminus Therapeutics is dedicated to developing cures for leukemia, focusing on their flagship product, ART714, which is designed to be a best-in-class treatment. The company's mission is to innovate and provide effective therapeutic solutions for leukemia patients, aiming to significantly improve patient outcomes in this specific medical field.

Geminus Therapeutics has made significant strides in leukemia treatment with ART714, positioning itself as a leader in the industry. The company's impact is reflected in its commitment to advancing leukemia therapies, contributing to the broader medical community's efforts to combat this disease.

Geminus Therapeutics - Similar Companies

Palm Therapeutics logo

Palm Therapeutics

Partner Therapeutics logo

Partner Therapeutics

partnertx.com

Geron logo

Geron

geron.com

Dual Therapeutics logo

Dual Therapeutics

Plumeria Therapeutics logo

Plumeria Therapeutics

Advanced Cancer Therapeutics logo

Advanced Cancer Therapeutics

GuideRx logo

GuideRx

Geneicd logo

Geneicd

G1 Therapeutics logo

G1 Therapeutics

g1therapeutics.com

Gemmus Pharma logo

Gemmus Pharma

Spheringenics logo

Spheringenics

Encoded Therapeutics logo

Encoded Therapeutics

LTZ Therapeutics logo

LTZ Therapeutics

Thelium Therapeutics logo

Thelium Therapeutics

Levo Therapeutics logo

Levo Therapeutics

Geminus Therapeutics - Quick Facts

Who are Geminus Therapeutics' competitors?

Companies similar to Geminus Therapeutics include Palm Therapeutics, Partner Therapeutics, Geron and Dual Therapeutics.

Where is Geminus Therapeutics' headquarters located?

Geminus Therapeutics' headquarters is located in Baltimore, MD, US.

When was Geminus Therapeutics' last funding round?

Geminus Therapeutics' most recent funding round was for $150k (USD) in November 2021.

How much has Geminus Therapeutics raised to-date?

As of Nov 22, 2021, Geminus Therapeutics has raised a total of $150k (USD).

How many employees does Geminus Therapeutics have?

Geminus Therapeutics has 50 employees as of Feb 4, 2024.

Geminus Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Main Product
  • Leukemia Treatment
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified